Bavarian Nordic Cuts Outlook on FDA Permit Delay

Danish biotech firm Bavarian Nordic lowered its financial guidance for 2009 on Friday because of a delayed U.S. permit for delivery of its Imvamune smallpox vaccine, knocking its shares 7 percent lower.
ForexYard